Ani Pharmaceuticals (ANIP) Non-Current Debt (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 14 years of Non-Current Debt data on file, last reported at $286.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 6.32% year-over-year to $286.0 million; the trailing twelve-month figure through Mar 2026 stood at $286.0 million (down 6.32% YoY), and the FY2025 full-year result was $291.8 million, down 5.59% from the prior year.
• Non-Current Debt retreated to $286.0 million in Q1 2026, from $291.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $312.9 million in Q3 2024 to a low of $284.4 million in Q2 2024.
• A 5-year average of $291.6 million and a median of $286.0 million in 2026 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 69.43% in 2022 and retreated 6.32% in 2026, its largest moves.
• Tracing ANIP's Non-Current Debt over 5 years: stood at $285.7 million in 2022, then decreased by 0.3% to $284.8 million in 2023, then grew by 8.53% to $309.1 million in 2024, then slipped by 5.59% to $291.8 million in 2025, then dropped by 2.0% to $286.0 million in 2026.
• Business Quant data shows ANIP's Non-Current Debt at $286.0 million in Q1 2026, $291.8 million in Q4 2025, and $297.7 million in Q3 2025.